StockNews.AI

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

StockNews.AI • 4 hours

DBVNVAXAMGN
High Materiality8/10

Information

Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Foll...

Original source

AI Summary

DBV Technologies raised €166.7 million from warrant exercises. Funding ensures operations and prepares for VIASKIN® launch in the U.S. Warrants fully exercised, issuing a total of 124 million new shares. Proceeds will support a potential Biologics License Application. Company forecasts sufficient cash for at least 12 months.

Sentiment Rationale

The successful funding demonstrates strong investor confidence, positioning DBVT well for regulatory success and commercial launch.

Trading Thesis

Immediate focus is on financing operations and upcoming product launch, potentially influencing share price soon.

Market-Moving

  • DBV Technologies raised €166.7 million from warrant exercises.
  • Funding ensures operations and prepares for VIASKIN® launch in the U.S.
  • Warrants fully exercised, issuing a total of 124 million new shares.

Key Facts

  • DBV Technologies raised €166.7 million from warrant exercises.
  • Funding ensures operations and prepares for VIASKIN® launch in the U.S.
  • Warrants fully exercised, issuing a total of 124 million new shares.
  • Proceeds will support a potential Biologics License Application.
  • Company forecasts sufficient cash for at least 12 months.

Companies Mentioned

  • DBV (DBV)
  • NVAX (NVAX)
  • AMGN (AMGN)

Corporate Developments

The exercise of warrants secures funding for critical operations, creating a positive sentiment around DBVT’s prospects and enhancing share valuation.

DBV Technologies Secures €166.7 Million from Warrant Exercised Financing

Châtillon, France - January 16, 2026 - DBV Technologies (Euronext: DBV – Nasdaq: DBVT), a late-stage biopharmaceutical company, has announced an impressive €166.7 million in gross proceeds. This financing comes from the full exercise of ABSA Warrants and BS Warrants associated with its March 2025 financing, positioning the company for significant advancements in its commercial strategy, particularly the potential launch of the VIASKIN® Peanut patch for children aged 4 to 7 in the U.S., pending approval.

Details of the Warrant Exercise

The total financing resulted from the inclusion of:

  • 34,090,004 ABSA Warrants, resulting in the issuance of 59,657,507 New Shares at an exercise price of €1.5939.
  • 71,005,656 BS Warrants, leading to the issuance of 71,005,656 pre-funded warrants (the “Second Pre-Funded Warrants”) at an exercise price of €1.5764, allowing the subscription for up to 124,259,898 New Shares.

This complete exercise indicates robust investor confidence and the successful execution of DBV's financial strategy to support operational readiness for the anticipated product launch.

Use of Proceeds and Financial Position

The gross proceeds of €166.7 million will primarily support:

  • Working capital and general corporate purposes.
  • Preparation and submission of a potential Biologics License Application (BLA).
  • Funding the launch of the VIASKIN® Peanut patch in the U.S., contingent upon regulatory approval.

Furthermore, if all outstanding Pre-Funded Warrants are exercised, DBV anticipates gross proceeds will reach approximately €168.2 million, totaling a potential financing of €284.5 million from this exercise.

Positive Outlook and 12-Month Projections

Based on its current operations and strategic plan, DBV Technologies is well-positioned with sufficient cash reserves to sustain operations for at least the next 12 months. This projection includes the anticipated launch of the VIASKIN® Peanut product, assuming regulatory approval is granted.

The company asserts that, as of today, there is no substantial doubt regarding its ability to maintain its status as a going concern, although it acknowledges potential risks based on its current business strategy and market conditions.

Trading and Shareholder Impact

All New Shares will be traded on Euronext Paris, maintaining the same ISIN code FR0010417345 and symbol “DBV.” The issuance of New Shares may impact existing shareholder equity and ownership percentages.

Key projections include:

  • Ownership interest for a shareholder holding 1.00% prior to issuance may drop to approximately 0.78% post-issue.
  • Shareholder equity per share is expected to adjust from around €0.22 to €0.37 on a non-diluted basis.

These figures reflect the dilution effect on existing shareholders and underscore the strategic nature of this financing to bolster the company’s operational capabilities.

Conclusion

DBV Technologies (DBVT) is set for transformative growth as it moves towards the potential launch of its innovative treatment for peanut allergies in children. The successful completion of this financing underscores the company’s robust market strategy and the confidence of its investors in its future potential.

Related News